David W. Schulz

Varenicline:  An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation

Jotham W. Coe, Paige R. Brooks, Michael G. Vetelino et al. · Journal of Medicinal Chemistry · 2005 · 929 citations · Full text

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

Hans Rollema, Leslie K. Chambers, J.W. Coe et al. · Neuropharmacology · 2006 · 532 citations

Tobacco Cessation, Molecular Pharmacology, Tobacco Control +9

CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.

David W. Schulz, Robert S. Mansbach, Jeffrey Sprouse et al. · Proceedings of the National Academy of Sciences · 1996 · 378 citations · Full text

Social Sciences, Molecular Pharmacology, Crf Receptors +17

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Thomas Seeger, P A Seymour, Anne W. Schmidt et al. · Journal of Pharmacology and Experimental Therapeutics · 1995 · 320 citations

Barbiturate enhancement of GABA-mediated inhibition and activation of chloride ion conductance: correlation with anticonvulsant and anesthetic actions

David W. Schulz, Robert L. Macdonald · Brain Research · 1981 · 203 citations

Chloride Ion Conductance, Barbiturate Enhancement, Neurophysiology +14